Aerovate Therapeutics Stock Investor Sentiment

AVTE Stock  USD 2.41  0.02  0.82%   
About 61% of Aerovate Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Aerovate Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Aerovate Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Aerovate Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
21 hours ago at gurufocus.com         
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates BRDG, AVTE, GB on Behalf of Shareholders
Gurufocus Stories at Macroaxis
a day ago at gurufocus.com         
Acquisition by Benjamin Dake of 20557 shares of Aerovate Therapeutics at 2.14 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates IVAC, AVTE, QTRX on Behalf of Shareholders
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
Deltec Asset Management LLC Invests 514,000 in Aerovate Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over three weeks ago at news.google.com         
Aerovate Therapeutics, Inc. Sees Significant Growth in Short Interest - MarketBeat
Google News at Macroaxis
over three weeks ago at thelincolnianonline.com         
Short Interest in Aerovate Therapeutics, Inc. Rises By 35.5
news
over three weeks ago at gurufocus.com         
SHAREHOLDER NOTICE Halper Sadeh LLC Investigates MHLD, IPG, AVTE on Behalf of Shareholders
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 12495 shares by George Eldridge of Aerovate Therapeutics at 31.2291 subject to Rule 1...
Macroaxis News
over a month ago at news.google.com         
Aerovate Therapeutics Target of Unusually Large Options Trading - MarketBeat
Google News at Macroaxis
over a month ago at news.google.com         
Disposition of 2051 shares by George Eldridge of Aerovate Therapeutics at 2.14 subject to Rule 16b-3
Google News at Macroaxis
over a month ago at businesswire.com         
AVTE Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc....
businesswire News
over a month ago at businesswire.com         
AVTE Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc....
businesswire News
over two months ago at gurufocus.com         
HAREHOLDER ALERT The MA Class Action Firm Continues To Investigate Merger - AVTE, BCOV, ...
Gurufocus Stories at Macroaxis
over two months ago at news.google.com         
Aerovate Therapeutics, Inc. Short Interest Down 5.3 percent in November - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
INVESTOR ALERT The MA Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVT...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Aerovate Therapeutics that are available to investors today. That information is available publicly through Aerovate media outlets and privately through word of mouth or via Aerovate internal channels. However, regardless of the origin, that massive amount of Aerovate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aerovate Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aerovate Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aerovate Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aerovate Therapeutics alpha.

Aerovate Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Aerovate Stock analysis

When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments